Carmen Mannucci

Dr. Carmen Mannucci

Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2015 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
Michele NavarraMichele Navarra
Michele Navarra
CMCarmen Mannucci
Carmen Mannucci
MDMarisa Delbò
Marisa Delbò
Gioacchino CalapaiGioacchino Calapai
Gioacchino Calapai
Citrus bergamia Risso et Poiteau, also known as “Bergamot”, is a plant belonging to the Rutaceae family, defined as a hybrid of bitter orange and lemon. It is an endemic plant of the Calabria region (Italy). Bergamot fruit is primarily used for the extraction of its essential oil (bergamot essential oil: BEO), employed in perfume, cosmetics, food and confections. The aim of this review was to collect recent data from the literature on Citrus bergamia essential oil and, through a critical analysis, focus on safety and the beneficial effects on human health. Clinical studies on the therapeutic applications of BEO exclusively focus on the field of aromatherapy, suggesting that its use can be useful for reducing anxiety and stress.

15 March 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
FCFabrizio Calapai
Fabrizio Calapai
LCLuigi Cardia
Luigi Cardia
ESEmanuela Elisa Sorbara
Emanuela Elisa Sorbara
Michele NavarraMichele Navarra
Michele Navarra
SGSebastiano Gangemi
Sebastiano Gangemi
CMCarmen Mannucci
Carmen Mannucci
Potential therapeutic actions of the cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are based on their activity as analgesics, anti-emetics, anti-inflammatory agents, anti-seizure compounds. THC and CBD lipophilicity and their neurological actions makes them candidates as new medicinal approaches to treat central nervous system (CNS) diseases. However, they show differences about penetrability and disposition in the brain. The present article is an overview about THC and CBD crossing the blood–brain barrier (BBB) and their brain disposition. Several findings indicate that CBD can modify the deleterious effects on BBB caused by inflammatory cytokines and may play a pivotal role in ameliorating BBB dysfunction consequent to ischemia. Thus supporting the therapeutic potential of CBD for the treatment of ischemic and inflammatory diseases of CNS. Cannabinoids positive effects on cognitive function could be also considered through the aspect of protection of BBB cerebrovascular structure and function, indicating that they may purchase substantial benefits through the protection of BBB integrity. Delivery of these cannabinoids in the brain following different routes of administration (subcutaneous, oral, and pulmonary) is illustrated and commented. Finally, the potential role of cannabinoids in drug-resistance in the clinical management of neurological or psychiatric diseases such as epilepsy and schizophrenia is discussed on the light of their crossing the BBB.

1 January 2018 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
CMCarmen Mannucci
Carmen Mannucci
FCFabrizio Calapai
Fabrizio Calapai
LCLuigi Cardia
Luigi Cardia
GIGiuseppina Inferrera
Giuseppina Inferrera
Giovanni D'ArenaGiovanni D'Arena
Giovanni D'Arena
Gioacchino CalapaiGioacchino Calapai
Gioacchino Calapai
Objective. The aim of this review is to analyze preclinical and clinical studies investigating the anxiety effects of Citrus aurantium or Citrus sinensis essential oils (EOs). Design. The bibliographic research was made on the major scientific databases. Analysis included only articles written in English and published on peer‐reviewed scientific journals describing preclinical experiments and clinical trials carried out to investigate the antianxiety effects of Citrus aurantium or Citrus sinensis EOs on anxiety disorders. Clinical studies reporting the antianxiety effects of products containing Citrus aurantium or Citrus sinensis EOs in combination with other active substances, including medicinal plants, were excluded. Nine clinical studies fulfilled the criteria adopted for analysis. Results. Data show that Citrus aurantium or Citrus sinensis EOs produce anxiolytic effects both in preclinical experiments and in different clinical conditions. Citrus aurantium EO aromatherapy reduced anxiety level in the great part of stress conditions studied (subjects affected by chronic myeloid leukemia and preoperative patients) except for a sample of patients subjected to colonoscopy. Exposition to Citrus sinensis EO in clinical studies shows to be positive in reducing anxiety level in patients waiting for dental treatment as well as in healthy volunteers submitted to an anxiogenic situation. Conclusions. Overview of clinical trials conducted with Citrus aurantium or Citrus sinensis on people with anxiety showed that inhalation or oral administration of Citrus aurantium and inhalation of Citrus sinensis can exert beneficial effects on anxiety; however, because of incomplete accuracy in the reporting of methodology, further more complete clinical studies are warranted.

17 October 2016 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
CMCarmen Mannucci
Carmen Mannucci
Michele NavarraMichele Navarra
Michele Navarra
FCFabrizio Calapai
Fabrizio Calapai
SRSqueri Raffaele
Squeri Raffaele
SGSebastiano Gangemi
Sebastiano Gangemi
Gioacchino CalapaiGioacchino Calapai
Gioacchino Calapai

8 October 2015 in BMC Immunology
Verified
Journal Article
Open access
PDF file
Lia GinaldiLia Ginaldi
Lia Ginaldi
MASSIMO DE MARTINISMASSIMO DE MARTINIS
MASSIMO DE MARTINIS
FCFedra Ciccarelli
Fedra Ciccarelli
SSSalvatore Saitta
Salvatore Saitta
SISelene Imbesi
Selene Imbesi
SGSebastiano Gangemi
Sebastiano Gangemi
Several inflammatory cytokines play a key part in the induction of osteoporosis. Until now, involvement of the Th2 cytokine interleukin-31 (IL-31) in osteoporosis hadn’t yet been studied. IL-31 is a proinflammatory cytokine mediating multiple immune functions, whose involvement in a wide range of diseases, such as atopic dermatitis, inflammatory bowel diseases and cutaneous lymphomas, is now emerging. Given the important role of IL-31 in inflammation, we measured its serum levels in postmenopausal osteoporotic patients. In fifty-six postmenopausal females with osteoporosis and 26 healthy controls, bone mineral density (BMD) measurements were performed by using calcaneal quantitative ultrasound (QUS) technique, confirmed at the lumbar spine and hip by dual energy X-ray absorptiometry (DXA). Both patients and controls were divided according to age (less or more than 65 years) and disease severity (T-score levels and presence of fractures). Serum IL-31 levels were measured by ELISA technique. Osteoporotic patients exhibited elevated levels of serum IL-31 compared with healthy controls (43.12 ± 6.97 vs 29.58 ± 6.09 pg/ml; p < 0.049). IL-31 expression was higher in over 65 years old patients compared to age-matched controls (45 ± 11.05 vs. 17.92 ± 5.92; p < 0.01), whereas in younger subjects no statistically significant differences were detected between patients and controls (37.91 ± 6.9 vs 32.08 ± 8.2). No statistically significant differences were found between IL-31 levels in patients affected by mild (T-score > -3) compared to severe (T-score < -3) osteoporosis (59.17 ± 9.22 vs 37.91 ± 10.52), neither between fractured and unfractured osteoporotic women (33.75 ± 9.16 vs 51.25 ± 8.9). We showed for the first time an increase of IL-31 serum levels in postmenopausal women with decreased BMD. Although they did not reflect the severity of osteoporosis and/or the presence of fractures, they clearly correlated with age, as reflected by the higher levels of this cytokine in aged patients.

16 October 2021 in Molecules
Verified
Journal Article
Open access
PDF file
ABAlessandra Bennici
Alessandra Bennici
CMCarmen Mannucci
Carmen Mannucci
FCFabrizio Calapai
Fabrizio Calapai
LCLuigi Cardia
Luigi Cardia
IAIlaria Ammendolia
Ilaria Ammendolia
DSDaniel Griscti Soler
Daniel Griscti Soler
Products derived from the plant Cannabis sativa are widely appreciated for their analgesic properties and are employed for the treatment of chronic neuropathic pain. Only nabiximols, a product composed of two extracts containing similar percentages of the two cannabinoids cannabidiol and delta-9-tetrahydrocannabinol, is approved by regulatory authorities for neuropathic pain and spasticity due to multiple sclerosis in many European countries and Canada. It is also included in pharmacovigilance systems monitoring the occurrence of adverse drug reactions. However, it is not the same for the great variety of other cannabis preparations widely used for medical purposes. This creates a situation characterized by insufficient knowledge of the safety of cannabis preparations and the impossibility of establishing a correct risk–benefit profile for their medical use in the treatment of chronic neuropathic pain. With the aim to explore this issue more deeply, we collected data on adverse reactions from published clinical studies reporting the use of cannabis for neuropathic relief.